From: Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
Number of patients | ||||||
---|---|---|---|---|---|---|
Overall | Pulmonary toxicity | non-Pulmonary toxicity | Odds ratio | 95% CI | P | |
Number of patients | 113 | 4 | 109 | |||
Age (year) | 0.36 | 0.03-3.62 | 0.62 | |||
<71 | 60 | 3 | 57 | |||
ā§71 | 53 | 1 | 52 | |||
Gender | 2.36 | 0.23-23.41 | 0.63 | |||
Female | 49 | 1 | 48 | |||
Male | 64 | 3 | 61 | |||
Smoking history | 1.80 | 0.18-17.9 | 1.00 | |||
No | 42 | 1 | 41 | |||
Yes | 71 | 3 | 68 | |||
Performance status | 0.34 | 0.28-31.0 | 0.37 | |||
0-1 | 101 | 3 | 98 | |||
2-3 | 11 | 1 | 10 | |||
Number of line | 0.57 | 0.05-5.71 | 1.00 | |||
1-2 | 72 | 3 | 69 | |||
3- | 41 | 1 | 40 | |||
IIPs | 11.8 | 1.17-119.6 | 0.03* | |||
No | 88 | 1 | 87 | |||
Yes | 25 | 3 | 22 |